Etanercept treatment in juvenile idiopathic arthritis: the Polish registry

Area of Science:

• Rheumatology
• Pediatric Rheumatology
• Immunology

Background:

• Juvenile idiopathic arthritis (JIA) poses long-term challenges for pediatric patients.
• Conventional disease-modifying antirheumatic drugs (DMARDs) are not always effective for all JIA subtypes.
• Evaluating novel therapeutic options is crucial for managing refractory JIA.

Purpose of the Study:

• To assess the long-term safety and efficacy of etanercept in Polish pediatric patients diagnosed with JIA.
• To determine the effectiveness of etanercept in patients who have not responded to methotrexate and other DMARDs.
• To analyze clinical and laboratory outcomes in JIA patients treated with etanercept.

Main Methods:

• The study included 188 pediatric patients meeting International League of Associations of Rheumatology (ILAR) criteria for JIA.
• Etanercept therapy was initiated after failure of methotrexate and other synthetic DMARDs.
• Disease improvement was evaluated using Giannini's criteria and ACR Pediatric criteria.

Main Results:

• Significant improvements in clinical and laboratory parameters were observed within the first month of etanercept treatment, sustained over time.
• High rates of ACR Pediatric 30, 50, 70, 90, and 100 responses were achieved by 24 months (94.7%, 88.4%, 62.1%, 34.7%, and 26.3%, respectively).
• Over a 72-month safety observation period, the exposure-adjusted adverse event rate was 2.96 per patient per year.

Conclusions:

• Etanercept provides significant and enduring improvements in disease activity for JIA subtypes resistant to conventional DMARDs.
• Combination therapy with etanercept and DMARDs was well-tolerated in this patient cohort.
• Etanercept represents a valuable therapeutic option for refractory pediatric JIA.